Back to top
more

NRx Pharmaceuticals (NRXP)

(Delayed Data from NSDQ)

$3.54 USD

3.54
278,922

+0.40 (12.74%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.75 +0.21 (5.93%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NRXP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

NRx Pharmaceuticals, Inc. [NRXP]

Reports for Purchase

Showing records 1 - 20 ( 31 total )

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 2

03/06/2024

Company Report

Pages: 5

Adjusting Our Cash Burn Down, Extending Runway

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 3

02/29/2024

Company Report

Pages: 6

A $1.5M Offering of Common Stock?

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 4

02/21/2024

Company Report

Pages: 6

HOPE at Bio CEO Conference

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 5

02/05/2024

Company Report

Pages: 6

NRx Spins Out Hope to Shareholders

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 6

01/22/2024

Company Report

Pages: 6

Announces Completion of Enrollment - P2B/3 NRX-101 in Suicidal Treatment-Resistant Bipolar Depression

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 7

01/19/2024

Company Report

Pages: 5

Looking For Hope to Spring in 2024; Reiterate Buy and $2.00 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 8

01/16/2024

Company Report

Pages: 6

Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 9

12/19/2023

Company Report

Pages: 6

NRXP Signs Agreement Access to Data Shows Efficacy Safety of IV Ketamine for the Treatment of Suicidal Depression

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 10

11/06/2023

Company Report

Pages: 6

NRx Pharmaceuticals Nephron Pharmaceuticals announce a Joint Agreement to Develop IV Ketamine

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 11

11/01/2023

Company Report

Pages: 6

Ketamine Manufacturing Could be Lucrative

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 12

10/26/2023

Company Report

Pages: 6

Study May Proceed (letter) - A New Way to Treat Pain

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 13

10/24/2023

Company Report

Pages: 5

Strategic Change Could Accelerate NRX-100’s Regulatory Path; Reiterate Buy and $2 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 14

10/16/2023

Company Report

Pages: 6

NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 15

10/02/2023

Company Report

Pages: 6

NRX-101 - IND Filed for Pain Indication but it’s Early Days

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 16

09/07/2023

Company Report

Pages: 6

Factoring in Future Dilution - Lowering Price Target - $9.0 to $2.0

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 17

08/15/2023

Company Report

Pages: 6

NRx Reports the Quarter

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 18

08/07/2023

Company Report

Pages: 6

NRx Licenses IP for NRX-101 for Chronic Pain

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 19

06/05/2023

Company Report

Pages: 6

NRx Licenses NRX-101 to Lotus - $330M in Milestones

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: NRx Pharmaceuticals, Inc.

Industry: Unclassified

Record: 20

05/25/2023

Company Report

Pages: 4

NRX-101’s Pathway May Be Poised to Accelerate; Reiterate Buy and $2.00 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party